Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

1.

Management of patients with Alzheimer's disease: pharmacological treatment and quality of life.

Mossello E, Ballini E.

Ther Adv Chronic Dis. 2012 Jul;3(4):183-93. doi: 10.1177/2040622312452387.

PMID:
23342234
[PubMed]
Free PMC Article
2.

Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.

Beier MT.

Pharmacotherapy. 2007 Mar;27(3):399-411. Review.

PMID:
17316151
[PubMed - indexed for MEDLINE]
3.

Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden?

Levy K, Lanctôt KL, Farber SB, Li A, Herrmann N.

Drugs Aging. 2012 Mar 1;29(3):167-79. doi: 10.2165/11599140-000000000-00000. Review.

PMID:
22350526
[PubMed - indexed for MEDLINE]
4.

Atypical antipsychotics for the treatment of dementia-related behaviors: an update.

Daiello LA.

Med Health R I. 2007 Jun;90(6):191-4.

PMID:
17633594
[PubMed - indexed for MEDLINE]
5.

The relationship between caregivers' global ratings of Alzheimer's disease patients' quality of life, disease severity, and the caregiving experience.

Karlawish JH, Casarett D, Klocinski J, Clark CM.

J Am Geriatr Soc. 2001 Aug;49(8):1066-70.

PMID:
11555068
[PubMed - indexed for MEDLINE]
6.

The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.

Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP.

Postgrad Med. 2005 Jan;Spec No:6-22.

PMID:
17203561
[PubMed - indexed for MEDLINE]
7.

Determinants of quality of life in Alzheimer's disease: perspective of patients, informal caregivers, and professional caregivers.

Gómez-Gallego M, Gómez-Amor J, Gómez-García J.

Int Psychogeriatr. 2012 Nov;24(11):1805-15. doi: 10.1017/S1041610212001081. Epub 2012 Jun 15.

PMID:
22697366
[PubMed - indexed for MEDLINE]
8.

Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

Standridge JB.

Clin Ther. 2004 May;26(5):615-30. Review.

PMID:
15220008
[PubMed - indexed for MEDLINE]
9.

Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale.

Matsui T, Nakaaki S, Murata Y, Sato J, Shinagawa Y, Tatsumi H, Furukawa TA.

Dement Geriatr Cogn Disord. 2006;21(3):182-91. Epub 2006 Jan 9.

PMID:
16401890
[PubMed - indexed for MEDLINE]
10.

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S.

Portland (OR): Oregon Health & Science University; 2010 Jul.

11.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
[PubMed - indexed for MEDLINE]
12.

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Cappell J, Herrmann N, Cornish S, Lanctôt KL.

CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000. Review.

PMID:
20932064
[PubMed - indexed for MEDLINE]
13.

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A.

Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000. Review.

PMID:
22480339
[PubMed - indexed for MEDLINE]
14.

Clinical practice guidelines for severe Alzheimer's disease.

Herrmann N, Gauthier S, Lysy PG.

Alzheimers Dement. 2007 Oct;3(4):385-97. doi: 10.1016/j.jalz.2007.07.007. Epub 2007 Sep 17.

PMID:
19595959
[PubMed]
15.

A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.

Kirbach S, Simpson K, Nietert PJ, Mintzer J.

Clin Drug Investig. 2008;28(5):291-303.

PMID:
18407715
[PubMed - indexed for MEDLINE]
16.

Screening for Dementia [Internet].

Boustani M, Peterson B, Harris R, Lux LJ, Krasnov C, Sutton SF, Hanson L, Lohr KN.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Jun.

17.

Navigating patients and caregivers through the course of Alzheimer's disease.

Aupperle PM.

J Clin Psychiatry. 2006;67 Suppl 3:8-14; quiz 23. Review.

PMID:
16649846
[PubMed - indexed for MEDLINE]
18.

Pharmacological treatment of Alzheimer's Disease.

Bianchetti A, Ranieri P, Margiotta A, Trabucchi M.

Aging Clin Exp Res. 2006 Apr;18(2):158-62. Review.

PMID:
16702787
[PubMed - indexed for MEDLINE]
19.

Behavioral effects of current Alzheimer's disease treatments: a descriptive review.

Cummings JL, Mackell J, Kaufer D.

Alzheimers Dement. 2008 Jan;4(1):49-60. doi: 10.1016/j.jalz.2007.10.011. Review.

PMID:
18631950
[PubMed - indexed for MEDLINE]
20.

Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.

Ballard C, Corbett A, Chitramohan R, Aarsland D.

Curr Opin Psychiatry. 2009 Nov;22(6):532-40. doi: 10.1097/YCO.0b013e32833111f9. Review.

PMID:
19696673
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk